Lung Cancer.pdf

Recommendations

Info

Table 9–5. (continued) Third-Generation Platinum-Containing Doublets versus Second-Generation Platinum-Containing Doublets Median 1-Year Side Effects Study and No. of Response Survival Survival P for Quality of Worse Than with Treatment Regimen Patients Rate Time Rate Survival Life Other Regimen Crino (1999) Cisplatin mitomycin/ ifosfamide 152 26% 9.6 months 34% Alopecia Cisplatin gemcitabine 155 38% (P .029) 8.6 months 33% .877 Same Thrombocytopenia Martoni (1998) NR Cisplatin epirubicin 95 33% 10.5 months Myelosuppression, alopecia Cisplatin vinorelbine 103 27% 9.6 months Takiguchi (2000) NR Cisplatin vindesine 101 22% 11.5 months 48% Neutropenia Cisplatin irinotecan 98 29% 10.4 months 43% .760 Diarrhea Belani (1998) NR Cisplatin etoposide 179 14% 9.1 months 37% Vomiting, myalgias Carboplatin paclitaxel 190 22% (P .059) 7.7 months 32% NR Neurotoxicity Danson (2001) Carboplatin gemcitabine 145 31% 7.3 months .273 Hematologic Cisplatin mitomycin C 151 34% 8.5 months ifosfamide OR cisplatin mitomycin C vinblastine * For cisplatin and etoposide versus cisplatin and paclitaxel 135 mg/m 2 . † For cisplatin and etoposide versus cisplatin and paclitaxel 135 mg/m 2 . ‡ When both paclitaxel arms combined compared with etoposide arm. P not reported for response or survival. Data from Schiller et al, 2000. Treatment of Patients with Advanced Non–Small Cell <strong>Lung</strong> <strong>Cancer</strong> 171
Table 9–6. Comparisons between Different Platinum–Third-Generation-Agent Doublets Median 1-Year Side Effects Study and No. of Response Survival Survival P for Quality Worse Than with Treatment Regimen Patients Rate Time Rate Survival of Life Other Regimen SWOG 9509 (Kelly, 2001a) Cisplatin vinorelbine 202 28% 8 months 36% Same Leukopenia, neutropenia, N/V, patients quit study because of toxicity Carboplatin paclitaxel 206 25% 8 months 38% — Neuropathy ECOG 1594 (Schiller, 2000) NR Cisplatin paclitaxel 292 21.3% 7.8 months 31% Cardiac, renal Cisplatin gemcitabine 288 21% 8.1 months 36% — Platelets, anemia, weakness Cisplatin docetaxel 293 17.3% 7.4 months 31% — Hypersensitivity reactions, renal Carboplatin paclitaxel 290 15.3% 8.2 months 35% N/V, renal EORTC 8975 (Van Meerbeeck, 2001) NR Cisplatin paclitaxel 153 31% 8.1 months 35.5% Cisplatin gemcitabine 158 36% 8.8 months 32.6% .9* Gemcitabine paclitaxel 157 27% 6.9 months (P .08) 26.5% .09† 172 R. Zinner
Page 1 and 2:
Lung Cancer Frank V. Fossella, MD R
Page 3 and 4:
This page intentionally left blank
Page 5 and 6:
Frank V. Fossella, MD Department of
Page 7 and 8:
vi Foreword possible. Since the res
Page 9 and 10:
This page intentionally left blank
Page 11 and 12:
x Contents Chapter 7 Surgical Treat
Page 13 and 14:
xii Contributors Joe B. Putnam, Jr.
Page 15 and 16:
2 J.B. Putnam, Jr., F.V. Fossella,
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
26 F.V. Fossella common sites of lu
Page 41 and 42:
28 F.V. Fossella history and physic
Page 43 and 44:
30 F.V. Fossella Computed Tomograph
Page 45 and 46:
32 F.V. Fossella Pulmonary Function
Page 47 and 48:
34 F.V. Fossella The use of flexibl
Page 49 and 50:
36 R.F. Munden and J.J. Erasmus hav
Page 51 and 52:
38 R.F. Munden and J.J. Erasmus che
Page 53 and 54:
40 R.F. Munden and J.J. Erasmus tha
Page 55 and 56:
42 R.F. Munden and J.J. Erasmus (Gu
Page 57 and 58:
44 R.F. Munden and J.J. Erasmus A B
Page 59 and 60:
46 R.F. Munden and J.J. Erasmus in
Page 61 and 62:
48 R.F. Munden and J.J. Erasmus Pat
Page 63 and 64:
50 R.F. Munden and J.J. Erasmus D C
Page 65 and 66:
52 R.F. Munden and J.J. Erasmus A B
Page 67 and 68:
54 R.F. Munden and J.J. Erasmus Bol
Page 69 and 70:
56 R.F. Munden and J.J. Erasmus Swe
Page 71 and 72:
58 P. Tamboli and J.Y. Ro Chapter O
Page 73 and 74:
60 P. Tamboli and J.Y. Ro Figure 4-
Page 75 and 76:
62 P. Tamboli and J.Y. Ro Postopera
Page 77 and 78:
64 P. Tamboli and J.Y. Ro Table 4-1
Page 79 and 80:
66 P. Tamboli and J.Y. Ro Atypical
Page 81 and 82:
68 P. Tamboli and J.Y. Ro Diffuse I
Page 83 and 84:
70 P. Tamboli and J.Y. Ro noma. Cig
Page 85 and 86:
72 P. Tamboli and J.Y. Ro Figure 4-
Page 87 and 88:
74 P. Tamboli and J.Y. Ro alone. BA
Page 89 and 90:
76 P. Tamboli and J.Y. Ro Other Mal
Page 91 and 92:
78 P. Tamboli and J.Y. Ro Electron
Page 93 and 94:
80 P. Tamboli and J.Y. Ro Niho S, Y
Page 95 and 96:
82 Y. De Jesus and G.L. Walsh Chapt
Page 97 and 98:
84 Y. De Jesus and G.L. Walsh Figur
Page 99 and 100:
86 Y. De Jesus and G.L. Walsh guide
Page 101 and 102:
88 Y. De Jesus and G.L. Walsh with
Page 103 and 104:
Figure 5-2. Patient “pathway to r
Page 105 and 106:
Page 107 and 108:
94 Y. De Jesus and G.L. Walsh Recov
Page 109 and 110:
Page 111 and 112:
98 Y. De Jesus and G.L. Walsh KEY P
Page 113 and 114:
100 Y. De Jesus and G.L. Walsh Jenn
Page 115 and 116:
102 W.R. Smythe nation for these su
Page 117 and 118:
104 W.R. Smythe patient reports of
Page 119 and 120:
106 W.R. Smythe bar or limited lung
Page 121 and 122:
108 W.R. Smythe hospitals for 149 p
Page 123 and 124:
110 W.R. Smythe Figure 6-1. Postsur
Page 125 and 126:
112 W.R. Smythe nant neoplasms has
Page 127 and 128:
114 W.R. Smythe Future Directions F
Page 129 and 130:
116 W.R. Smythe Henschke CI, McCaul
Page 131 and 132:
7 SURGICAL TREATMENT OF LOCALLY ADV
Page 133 and 134: 120 S.G. Swisher Treatment Options
Page 135 and 136: 122 S.G. Swisher Initial Assessment
Page 137 and 138: 124 S.G. Swisher Figure 7-1. Region
Page 139 and 140: 126 S.G. Swisher Table 7-2. (contin
Page 141 and 142: 128 S.G. Swisher upper paratracheal
Page 143 and 144: 130 S.G. Swisher is performed only
Page 145 and 146: 132 S.G. Swisher chance for long-te
Page 147 and 148: 134 S.G. Swisher Pancoast tumors th
Page 149 and 150: 136 S.G. Swisher A B Figure 7-2. Do
Page 151 and 152: 138 S.G. Swisher a combination of t
Page 153 and 154: 140 S.G. Swisher Dartevelle PG, Cha
Page 155 and 156: 8 NONSURGICAL TREATMENT OF EARLY-ST
Page 157 and 158: 144 R. Komaki morbid conditions pre
Page 159 and 160: 146 R. Komaki and 26 patients had c
Page 161 and 162: 148 R. Komaki Around 1998, by using
Page 163 and 164: 150 R. Komaki Table 8-5. Survival a
Page 165 and 166: 152 R. Komaki A total of 610 patien
Page 167 and 168: 154 R. Komaki tially obstructed air
Page 169 and 170: 156 R. Komaki report of Radiation T
Page 171 and 172: 9 TREATMENT OF PATIENTS WITH ADVANC
Page 173 and 174: 160 R. Zinner chemotherapy, in pati
Page 175 and 176: Table 9-1. Chemotherapy in Older Pa
Page 177 and 178: 164 R. Zinner results of additional
Page 179 and 180: Table 9-3. Third-Generation-Agent M
Page 181 and 182: Table 9-4. Third-Generation Agents
Page 183: Table 9-5. Third-Generation Platinu
Page 187 and 188: 174 R. Zinner may play an important
Page 189 and 190: Table 9-8. Third-Generation Cisplat
Page 191 and 192: 178 R. Zinner wards higher survival
Page 193 and 194: 180 R. Zinner KEY PRACTICE POINTS
Page 195 and 196: 182 R. Zinner DeVore RF, Fehrenbach
Page 197 and 198: 184 R. Zinner Perng RP, Chen YM, Mi
Page 199 and 200: 10 TREATMENT OF LIMITED-STAGE SMALL
Page 201 and 202: 188 R. Komaki Age is not a signific
Page 203 and 204: 190 R. Komaki lished between 1979 a
Page 205 and 206: Table 10-1. Complete Response Rates
Page 207 and 208: 194 R. Komaki twice daily to a tota
Page 209 and 210: 196 R. Komaki Intergroup study 0096
Page 211 and 212: 198 R. Komaki Figure 10-1. Survival
Page 213 and 214: 200 R. Komaki cisplatin with concur
Page 215 and 216: 202 R. Komaki KEY PRACTICE POINTS
Page 217 and 218: 204 R. Komaki tients (Pts) with lim
Page 219 and 220: 206 R. Komaki Wagner H, Kim K, John
Page 221 and 222: 208 G.R. Blumenschein, Jr. recurs a
Page 223 and 224: 210 G.R. Blumenschein, Jr. syndrome
Page 225 and 226: 212 G.R. Blumenschein, Jr. toxicity
Page 227 and 228: 214 G.R. Blumenschein, Jr. the year
Page 229 and 230: 216 G.R. Blumenschein, Jr. is chara
Page 231 and 232: 218 G.R. Blumenschein, Jr. new cyto
Page 233 and 234: 12 PALLIATIVE CARE IN PATIENTS WITH
Page 235 and 236:
222 J.B. Putnam, Jr. therapy. Patie
Page 237 and 238:
224 J.B. Putnam, Jr. tion—includi
Page 239 and 240:
226 J.B. Putnam, Jr. rates were 47%
Page 241 and 242:
228 J.B. Putnam, Jr. Dyspnea The ma
Page 243 and 244:
230 J.B. Putnam, Jr. Small-bore cat
Page 245 and 246:
232 J.B. Putnam, Jr. A B Figure 12-
Page 247 and 248:
234 J.B. Putnam, Jr. C D Figure 12-
Page 249 and 250:
236 J.B. Putnam, Jr. B Figure 12-3.
Page 251 and 252:
238 J.B. Putnam, Jr. KEY PRACTICE P
Page 253 and 254:
240 J.B. Putnam, Jr. Rendina EA, De
Page 255 and 256:
242 A.A. Vaporciyan, J.F. Kelly, an
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
14 PREVENTION AND EARLY DETECTION O
Page 271 and 272:
258 E.S. Kim and F.R. Khuri A secon
Page 273 and 274:
260 E.S. Kim and F.R. Khuri Smoking
Page 275 and 276:
262 E.S. Kim and F.R. Khuri Reversa
Page 277 and 278:
264 E.S. Kim and F.R. Khuri yet to
Page 279 and 280:
266 E.S. Kim and F.R. Khuri nation
Page 281 and 282:
268 E.S. Kim and F.R. Khuri Methodo
Page 283 and 284:
270 E.S. Kim and F.R. Khuri have be
Page 285 and 286:
272 E.S. Kim and F.R. Khuri the tre
Page 287 and 288:
274 E.S. Kim and F.R. Khuri changes
Page 289 and 290:
276 E.S. Kim and F.R. Khuri KEY PRA
Page 291 and 292:
278 E.S. Kim and F.R. Khuri Hong WK
Page 293 and 294:
15 MOLECULAR EVENTS IN LUNG CANCER
Page 295 and 296:
282 W.N. Hittelman, J.M. Kurie, and
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
300 Index Anterior spinal column re
Page 315 and 316:
302 Index Cardiac murmurs, 104 Card
Page 317 and 318:
304 Index Diagnosis. See also under
Page 319 and 320:
306 Index Growth. See Tumor growth
Page 321 and 322:
308 Index Magnetic resonance (MR) i
Page 323 and 324:
310 Index p16 gene, 285 p19 arf gen
Page 325 and 326:
312 Index Pulmonary resection (cont
Page 327 and 328:
314 Index Squamous metaplasia, 263-
Page 329:
316 Index Vitamin A, 262 Vocal cord
show all

Lung Cancer.pdf

Create successful ePaper yourself

Delete template?

Save as template?